This retrospective matched case-control study examined factors associated with immediate extubation after heart transplantation (IEAHT) in adults. The authors report an exploratory analysis performed on cases from August 2018 through March 2025. The primary observation was an association between remifentanil-based total intravenous anesthesia (TIVA) and extubation in the operating room rather than delayed extubation in the intensive care unit (ICU).
The investigation followed prior favorable experiences with IEAHT in a pediatric patient and sought to evaluate applicability in adult heart transplant recipients. The work is presented as an exploratory cohort study; the source emphasizes the need for larger, prospective randomized trials to confirm safety and efficacy.
The study design was retrospective, matched, and case-control in nature. Eight adult patients who were extubated in the operating room (case group) were matched 1:3 with 24 patients who remained intubated and were extubated in the ICU (control group). Matching details (matching criteria) were not reported in the abstract.
Investigators collected demographic information, operative characteristics, anesthetic techniques including use of remifentanil-based TIVA, measures of opioid exposure, and postoperative outcomes. The time window for included procedures was August 2018 to March 2025.
Use of remifentanil-based TIVA differed markedly between groups: all 8 patients in the operating-room extubation group received remifentanil-based TIVA (8/8, 100%) versus 6 of 24 patients in the ICU-extubation group (25%). This difference was statistically significant (p = 0.001) according to the reported data.
Among patients who received remifentanil-based TIVA, the study reports that total opioid consumption did not differ significantly between the groups (p = 0.852). The abstract does not provide absolute opioid dose values or infusion regimens in the text provided.
Operative characteristics also varied between the groups. The case group had a shorter median cardiopulmonary bypass time (105 minutes) compared with the control group (155 minutes); this difference reached statistical significance (p = 0.004). Median operative time was also shorter in the case group (249 minutes) versus the control group (329 minutes), with p = 0.012.
The abstract reports the lack of a significant difference in total opioid consumption among those receiving remifentanil-based TIVA, but specific consumption values, weight-adjusted dosing, or cumulative intra- and postoperative opioid metrics were not provided in the abstract.
According to the reported results, there were no significant inter-group differences in postoperative complications or lengths of stay. The abstract does not list specific complications, rates, or numerical lengths of stay. Details such as ICU duration, hospital length of stay, reintubation rates, hemodynamic outcomes, or graft-specific endpoints are not reported in the abstract text provided.
In this exploratory cohort, the authors concluded that remifentanil-based TIVA was associated with operating-room extubation after heart transplantation. They suggest that remifentanil-based TIVA may be a feasible approach for selected patients seeking immediate extubation, but they explicitly state that confirmation of safety and efficacy requires adequately powered prospective randomized trials.
The authors position these findings as preliminary and hypothesis-generating rather than definitive practice-changing evidence.
The source describes the study as small, retrospective, and exploratory. Key limitations implied by the design include limited sample size (8 cases vs. 24 controls), potential selection and confounding biases inherent to retrospective matched case-control studies, and incomplete reporting of some methodological details in the abstract (for example, matching criteria and detailed opioid dosing). The abstract notes that safety and efficacy should be confirmed in prospective randomized studies, indicating the authors recognize the need for higher-quality evidence before broad implementation.
Overall, the available data from the abstract indicate an association between remifentanil-based TIVA and operating-room extubation in this cohort of adult heart transplant recipients, with shorter operative and cardiopulmonary bypass times observed in the extubated-in-OR group. No between-group differences in postoperative complications or length of stay were reported in the abstract. Further detailed data and randomized trials are needed to establish causality, define optimal patient selection, and evaluate safety outcomes more comprehensively.